crisaborole
NDA- Indications
- Atopic dermatitis, Psoriasis
Company intelligence / Profile preview
Anacor Pharmaceuticals
Palo Alto, California, United Statespfizer.com ↗
- Ownership
- Private
- Employees
- ~150
- Development stage
- NDA
01
Overview
Crisaborole achieved statistically significant results in Phase III trials for mild-to-moderate atopic dermatitis. The New Drug Application had been accepted by the FDA with a PDUFA date of January 2017. Kerydin was already approved as a topical antifungal. Pfizer expected peak sales of crisaborole to reach or exceed $2 billion annually if approved.
- Therapeutic areas
- DermatologyInfectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Anacor Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anacor Pharmaceuticals.